, , ,

<<


 >>  ()

-

12005

2

2005

-

# 1, 2005

, - . - (,,,,, -.). # 1, 2005,,,,.,. ( ),,. ( ).

. ( ),. 70.,,.,,... ( ),. ( ) -. ( ) -.,. ( ).

,,. ( ). ( ),. ( ), ( ). ( ). ( ) -.

. ( ). ( ). ). ( ) :

: 1014,. - :

: + (99412) 4957978;

, 0164, : +(99412) 4958468.

. : +(99532) 950221 : 375108,. : +(99532) 953564 : +(3741) 342710;

Email: journal.dv@gmail.com : +(3741) 350241.

# 1,.............. .........................................................................................................................................................................................................................................................................................................................................................................................................,...... Mycoplasma hominis Ureaplasma urealyticum.......................................................................... .....................................................................................................................,............................ .......................................................................................................................................................................................................................................... .............. # 1, -........................................................................................................................ c................................................................................................................................................................................................................................................................................................................................................................................................. :................................................................................................................................................................................................................................................................................. 5....................................................................................................................................................................................................................................................................................................................................................................................... ......................................................................................................,., -.

# 1,, !

70.,.,,.,,, ,,,.

,,,,, -.

.,,.,,.,,,,. .,,,,.

.C.,,.,,, -.

,,.

.

...

# 1,,.

-., -., -.,.,.,,,,.

, 2004,.

,, - -2005, -.

,, -.

-.,,.,.

70-.

...

# 1, !

- 70- -.

(1930 ),,.,.

60-.

, ( -,,,, )., -.,,.,,,.

80-.,.

.

, -,,.

,.

,,.

,,..., # 1,, - - 70-.

.

,,,,.

,,,,,.

-,,,..

# 1,.,.

-,,, (, - ),, -,., -,, -,. (2004.) , - :, : -,.

( ), ( ),, ( ).,, -,, -, :,.

:. - [1,2]. - ( ).

, -, -.,, -.

-, - (., ) [4].

- : - -,, -,.

- : - - - (,.

) ( -, - ) [3].,, ( # 1,,, -, 75 %, ) (,,, ). -.

,, - 10-20% -, - [5,6].

., -,, -, - -, [3,5]., : Candida.

10 30-45%. 5% - (.1).

1.

I :

, 1. ( ), 2.

- // 3..

- // 4.

5.

( ) - 6.

II,,, 1.

2., -.., -.,. -.

-. -.

# 1, :.

:, -., -, -,, ( T.vaginalis, -. ) [4]: 1. -. - ;

. 2., , (1% ) ( - 40-60%);

,. 3. ( - - 95%). -,,,., - - -.. (2003 ), ( - );

[5,6].. -,, -, : [8,11,12,13].

1. ;

2., ( - );

3. ( Candida / ) [5,6]..

, Candida - :

.,, -, -.

- [4]:

. - - 400-500, - 5- - -,,,. - -., ( -,,, ) -,, ( -., ). - T. vaginalis.

- 100,,.

(, ), - 20, -. # 1, 5 -,.

.,, - -,, -. [9]..

( ),. -,.

( - ) [5,6]: [6].

- 0,75%, 5 -, 1 ( ) 6 ;

,, - 2%, 5,0 ( ) -, 1 ( ) 6., -, 500. -.

,,. -,. (,,,,,, ),, :

-, 500 (,,.). 200 1 ;

, - -,, 1200,, - 400 1 3.

, 14-54% [5]. C - ( ), ( - )., - :

. - 150 ;

- 100 1 ;

. -, 200 2 2-, - [6,10].

,,,,,,.,,. 6 , 100 1,, -, -, 500 1.

, -, ( ),, -,.

- :

- -,, -.,, - # 1, (.. 1)., -,,, ( - - ),, -..

-,.

* **, / / () :,, / *.,, 2 : 21,, 3, 3.

**..

.

# 1, 1..,.,... M., 2...,.... IX,. 2, 2005.

3...,...

. 2001, 3, 2.

4. .... 2005;

2: 130 45.

5. Centers for Disease Control: Sexually transmitted diseases. MMWR 1998;

2: 61-63.

6.,.. 2004.111.

7...,... 2005, 3, 7.

8. Xia Zhou, Stephen J. Bent, Maria G. Schneider, Catherine C. Davis, Mohammed R. Islam and Larry J. Forney.

Characterization of vaginal microbial communities in adult healthy women using cultivation-independent methods Department of Biological Science, University of Idaho, Moscow, ID, USA. 9. Meri T, Jokiranta TS, Suhonen L, Meri S.Resistance of Trichomonas vaginalis to Metronidazole: Report of the First Three Cases from Finland and Optimization of In Vitro Susceptibility Testing under Various Oxygen Concentrations. J Clin Microbiol 2000;

38 (2): 763-7.

10. Daniels D, Forster G. National guideline for the management of vulvovaginal candidiasis. Sex Trans Inf 1999;

(suppl.1);

S19- 11...,.... 5, 2000.

12.....

8-, 18-22, 2001.

13...... ., 2003.

# 1, .

,, ( )-, ).

-, 20-30., 90% -,. -.

,, -.,,.. -,,, -,. IgE, D4+ - -.

, - :, -.. 91 102, -, - Sigurdsson V. et al. [1996], 43%.

- 18%,. 74%,,.. . -. - 2-4:1.

- (, - 40, ),, ( -,, ) ( -. ) -,,.

... -.

, - , (,,,,, -, ).

. . -, ( - ).

., , (,,,, -,, # 1,., , - - ,,, ,. -, ( - ), ., , , - ,,.,.

( ) : 30%, - 28%, 2%, 3%,. 10%, 14%, 2-6 - 8%.

.. . , -.

,,,..

- :

, ,,., ;

, (, Ig E ), - ;

,. , -,. ;

. ,, ,- -,., ;

. - ;

. ( - ;

). - :.,,,,. - -,.

(, - ( ),, -,. -, ),..

-,, -., -,., (, -,,.,,,, ). : - -,.

;

-, # 1,., -, ).,,. : -, -.

. -,.

, -,,, - 40%. -.

, :. -, - -,.,. - -.

(, - - ).. 50%,,. ( ). - -., ( -., ).,, -,,.

. -., -. (,, - )..

.

-..,,. -.

, -. -.,,. (-.

), 2-3.

( 0,025 . 1.0%) ( ),,,. -, -.,., - (,, ).. -,, - 5,. - 10. 20-40%;

, - 20%.

. -.

-,..,. -, 30-40%. (,,.

# 1, 1. Erythroderma. A clinicopathological study of 56 cases / Botella-Estrada R., Sanmartin O., Oliver V. et al. // Arch.

Dermatol. 1994. Vol. 130, N 12. P. 1503-1507.

2. Erythroderma: analysis of 247 cases / Vasconcellos C., Domingues P.D., Aoki V. et al. // Rev. Saude Publica. 1995.

Vol. 29, N 3. P. 177-182.

3. Erythroderma. A clinical and follow-up study of 102 patients, with special emphasis on survival / Sigurdsson V., Toonstra J., Hezemans-Boer M., van Vloten W.A. // J. Am. Acad. Dermatol. 1996. Vol. 35, N 1. P. 53-57.

4. Erythroderma: a comparison between HIV positive and negative patients / Morar N., Dlova N., Gupta A.K. et al. // Int. J. Dermatol. 1999. Vol. 38, N 12. P. 895-900.

5. Erythroderma with immunoglobulin deposits along the basal membrane. Pemphigoid erythroderma? / Scrivener Y., Cribier B., Le Coz C. et al. // Ann. Dermatol. Venereol. 1998. Vol. 125, N 1. P. 13-17.

6. Freedberg I.M. Exfoliative dermatitis. In: Freedburg I.M., Fitzpatrick T.B., Goldsmith L.A. et al., eds. Fitzpatricks Dermatology in General Medicine. - 5th ed. - McGraw-Hill, 1999. P. 534-537.

7. Generalised exfoliative dermatitis - a clinical study of 108 patients / Wong K.S., Wong S.N., Tham S.N., Giam Y.C.

// Ann. Acad. Med. Singapore. - 1988. - Vol. 17, N 4. - P. 520-523.

8. Grifths T.W., Stevens S.R., Cooper K.D. Acute erythroderma as an exclusion criterion for idio-pathic CD4+ T lymphocytopenia // Arch. Dermatol. 1994. Vol. 130, N 12. P. 1530-1533.

9. Heteroduplex analysis of T-cell receptor gamma gene rearrangement as an adjuvant diag-nostic tool in skin biopsies for erythroderma / Cherny S., Mraz S., Su L. et al. // J. Cutan. Pathol. 2001. Vol. 28, N 7. P. 351-355.

10. Histopathology in erythroderma: review of a series of cases by multiple observers / Walsh N.M., Prokopetz R., Tron V.A. et al. // J. Cutan. Pathol. 1994. Vol. 21, N 5. P. 419-423.

11. Horiuchi Y., Tsukahara T., Otoyama K. Immunohistochemical study of elevated expres-sion of squamos cell carcinoma (SCC)-related antigens in erythrodermic epidermis // J. Dermatol. 1994. Vol. 21, N 2. P. 67-72.

12. Sarcar R., Sharma R.C., Koranne R.V., Sardana K. Erythroderma in children: a clinico-etiological study // J. Dermatol.

1999. Vol. 26, N 8. P. 507-511.

13. Scott L., McClain S.A., Clark R.A.F. Transient eruptive seborrheic keratoses associated with erythrodermic psoriasis and erythrodermic drug eruption: Report of two cases // J. Am. Acad. Dermatol. 2001. Vol. 45. P. 212-214.

14. Sehgal V.N., Srivastava G. Exfoliative dermatitis. A prospective study of 80 patients // Dermatologica. 1986. Vol.

173, N 6. P. 278-284.

15. Sigurdsson V., Steegmans P.H.A., Van Vloten W.A. The incidence of erythroderma: A survey among all dermatologists in The Netherlands // J. Am. Acad. Dermatol. 2001. Vol. 45. P. 675-678.

16. Psoriatic erythroderma: a histopathologic study of forty-ve patients / Tomasini C., Aloi F., Solaroli C., Pippione M.

// Dermatology. 1997. Vol. 194, N 2. P. 102-106.

17. Zackheim H.S., Kashani-Sabet M., Hwang S.T. Low-dose methotrexate to treat erythrodermic cutaneous T-cell lymphoma: results in twenty-nine patients // J. Am. Acad. Dermatol. 1996. - Vol. 34, N 4. P. 626-631.

18. Zip C., Murray S., Walsh N.M. The specicity of histopathology in erythroderma // J. Cutan. Pathol. 1993. Vol.

20, N 5. P. 393-398.

ERYTHRODERMA AN URGENT CONDITION IN DERMATOLOGY U. P. Adaskevich Medical University of Vitebsk, Belarus Erythroderma or exfoliative dermatitis is a severe and sometimes life threatening condition characterized by a universal inammatory affection of the skin, generalized lympha-denopathy and fever. Erythrodermic dermatosis present serious problems because of their com-plicated diagnostics and therapy. The clinical pattern of erythroderma is fascinating because of its constantly changing scenario and the variety of factors responsible for the causation of this extensive skin disorder. The management of the condition remains a challenge and requires up-dating of the information available on erythroderma.

# 1,.,.,.

, -,., 50-70%. -, -,.,,, -,, -.

.,, -.,.,.,,,,., -.,. , - : ( ), , - (, - ) ( - ).

,.

,.

- (.

,, -, ).

: , ;

: ;

,, ;

/ .. - # 1, .

.

,, 4 :,,.,. (1984.

1996..),, : 2.- 7 ;

0,2.-7-14.

,.. (1990.), 60-75%. 96,6%,,, 15% (.. 1990 ).,, :

. ., ,.

,, . ., .

.,,. 1999,., -,,.

,.

:

( ;

) ( ;

)., .

.

:

:

.

187, . , :

.

# 1, ,. ( -.

);

( -.

) ;

1:

- - 1%, 1,0. N10-1.1 /, / ( ). -500 N30- 1 2 /.

,, - 36., - 2:

, 3 - N10 ( ). - -500 N 30- 1 2/ - 71,, - 3:

N10 ( ). C 0,25 N20- 1 2/ : 1- - 80 14, 1.

, - ( 2-3) - - 50-60%, - (,, - ) 1:64 1:32 (, - - , Ig G Ig M, - G ). 1-3,.

,,-. -,,.,. - - -.

1. 2. 3.

# 1, ( );

: ( -, NK- - :,, ) .

, - .

;

,.

(,, ) -.

( ) -.

-, -,.,., - 1.

2( / + ) 3( -, / + ). 1 ( + ) -,.,.

# 1, 1. Ramirez J. Advances in antibiotic use: switch therapy. Curr Ther Res 1993;

55(A):30-4.

2. Janknegt R, van der Meer JWM. Sequential therapy with intravenous and oral cephalosporins. J Antimicrob Chemother 1994;

33:169-77.

3. Hendeles L. Need for counter-detailing antibiotics. Am J Hosp Pharm 1976;

33:918-24.

4., 1997, 40.

5. Cohen R. Shortened therapies in acute otitis media. Hospital practice 1996;

31(1):5-10.

6. Khong TK. Shortened therapies in acute sinusitis. Hospital practice 1996;

31(1):11-3.

7. Pichichero ME. Shortened regimens for pharyngitis/tonsilitis. Hospital practice 1996;

31(1):14-20.

8. Felstead SJ, Azithromycin LRTI Study Group. Double-blind comparison of azithromycin and amoxicillin in the treatment of lower respiratory tract infections. Abstract. Proceedings of the 6th International Congress of Infectious Diseases, 1990.

9. Mertens JCC et al. Double-blind, randomized study comparing the efcacies and safeties of a short (3-day) cource of azithromycin and a 5-day cource of amoxicillin in patients with acute exacerabrations of chronic bronchitis.

Antimicrobial Agents and Chemotherapy 1992;

36:1446-59.

10. Lasus A. Comparative studies of azithromycin in skin and soft-tissue infections and sexually transmitted infections by Neisseria spp. and Chlamydia spp. J Antimicrob Chemother 1990;

25(A):115- 11. ( )/.

...,.: , 2000;

12. McConnell JD, Barry MJ, Bruskewitz RC. Benign prostatic hyperplasia: diagnosis and treatment. Agency for Health Care Policy and Research. Clin Pract Guidel-Quick Ref Guide for Clin 1994;

1 13. Johnson NJ, Kirby R. Cost-effectiveness analysis of alpha blocker therapy for the treatment of benign prostatic hyperplasia. European Urology 1996;

30 (Suppl. 2): 152 (

Abstract

N 543), XIIth Congress of the European Association of Urology, Paris, France, Sept 14,1996.

14. Altwein JE. Cost savings afforded by doxazosin monotherapy in concomitant benign prostatic hyperplasia and hypertension/European Urology 1996;

30 (Suppl. 2): 152 (Abstract N 542), XIIth Congress of the European Association of Urology, Paris, France, Sept 14, 1996.

15. Lepor H, Sypherd D, Machi G. Et al. Randomized Double Blind Study Comparing the Effectiveness of Balloon Dilation of the Prostate and Cystoscopy for the Treatment of Symptomatic Benign Prostatic Hyperplasia/Gen Urol 1992;

147: 63942.

16. Ilker Y, Tarcan T, Akdas A. Economics of Different Treatment Options of Benign Prostatic Hyperplasia in Turkey/Int Urol Nephrol 1996;

28: 5258.

17. Naslund M. A New Valuation Model for BPH from the Patient and Employer Perspective. J Urol 1996;

(Suppl.682A).

18. Roehborn C, Bergner B, Giddelman G. et al. Serum Prostate Specic Antigen And Prostate Volume Predict Long Term Changes In Symptoms And Flow Rate: Results of a 4 year, Randomized Trial Comparing Finasteride Versus Placebo. Urology 1999;

54: 662 19. Anderssen J, Nickel C, Marshall B. et al. Finasteride Signicantly Reduced Acute Urinary Retetion And Need For Surgery In Patients With Symptomatic Benign Prostatic Hyperplasia. Urol 1997;

49: 83945.

20. McConnel J, Druskewitz R, Walsh P. et al. The Effect of Finasteride on the Risk of Acute Urinary Retention And The Need For Surgical Treatment Among Men With Benign Prostatic Hyperplasia. New Engl J Med 1998;

338: 55763.

21. Albertsen T, Tellissier J, Lowe F. et al. Economic Analysis of Finasteride: A Model-Based Approach Using Data From The Proscar Long-Term Efcacy and Safety Study. Clin Ther 1999;

21: 100624.

22. Recommendations of 5 International Consultation on Benign Prostatic Hyperplasia (BPH) June 2528, 2000, Paris.

In: Benign Prostatic Hyperplasia eds. C.Chatelain, L.Denis, KT.Foo, S.Knoury, J.Mc Connell. Health Publication Ltd 2001;

535.

23. Clifford GM, Farmer RDT. How Do Symptoms Indicative of BPH Progress in Real Life Practice? The UK Experience.

Eur Urol 2000 Nov;

38 (Suppl S1): 4853.

24. Caine M, Pfau A, Perlberg S. The use of alpha adrenergic blockers in benign prostatic obstruction # 1, PHARMACOLOGICAL ASPECT OF UROGENITAL CHLAMIDIOSIS TREATMENT O IN ANDROLOGICAL PRACTICE N. Rusadze S/R Institute of Dermatology and Venereology Choosing method of treatment in patients with urogenital chlamidiosis depends on many factors of medical, economical and social character. Decision that made in everyday medical practice frequently based on doctors personal experience and conclusion. In this case medicine based on evidence and data of clinical efciency and safety of treatment obtained during randomized clinical trials on signicant amount of patients becomes very important.

In our study weve conducted pharmacoeconomical analysis of three methods of treatment of urogenital chlamidyosis. Analysis has shown that second(Glutoxim/Neovir+Cyprobai) and third(Glutoxim/Neovir+Sumamed)prevail over rst method (Glutoxim+Vilprafen)only by pharmacoeconomical index, but summarizing such data as repeated treatment with use of combined antibacterial therapy, low cure percentage, lost of work time etc, has shown that expenses signicantly exceed analogous expenses in method 1.

In conclusion taking in consideration clinical and pharmacoeconomical indexes use of Glutoxim Vilprafen in treatment of urogenital chlamidyosis is more advisable.

# 1,.

-,, - 91 (40,3%), II - - 78 (34,5%), III - 57 (25,2%).. - 40 -..

, - 2 : (CD3+, CD4+, CD8+, CD16+, CD25+, CD71+, CD95+,., - HLA-DR). - ( ), FITC, [2,6,10]., - Counter Epicx - XL Becton Dickinson( ). (,.) ( )- -1b, -2, -6, -8 [1,7,9]., ProCon Il,, - (, ).. -., - - Multiscan. -., - - Statistica (StatSoft, USA), -..

-.., -,..

. - ( 0,05),..

. - CD4+, CD16+, HLA-DR 226 -, CD25+.

. 16 (I ) ) CD8+ 55, - 36,59,8. - (1,2 CD4+ (157 ), (69). -. 3 :I - - # 1, - III. II., (CD4+) - - - -6 1,2%.

1,04 - (CD8+) - - (10,6%, 0,05). III -., - - 3,3%. -,, -. (CD4+/CD8+) - I - I II.

/ 18,5%,, - 8,3%, 19,3%,, -, -. -.. HLA-DR. - -1, 6 8 -2, HLA-DR. - - - (CD8+), HLA CD25+. - DR -2. HLA-DR CD25+ 18,4%, - - CD3+, CD4+, CD8+, CD16+,..

HLA-DR 16,4 13,2%. - -.

, -2 - CD25+. CD25+, HLA-DR 1,2 -8. -, CD25+ ( 0,05), (II III ). - 11,2% 6,4%. I -, CD95+-, -. CD8+ CD4+,. -, -,.

CD8+ 6,9%..

, -,, HLA-DR-, 1- -, - -( ),, [3,4,8]. - ( ).

1, 2, 6 8. 2. :,, -1 -, -.

II (17,1%) - (2,6%) (19,0%). -. 14,1%. -1 -,, - -.

. -2 II., - - 12,0% ( 0,05) -,., -6 -8 II -. 9,5% 10,6% ( 0,05) -,. -,.

# 1, # 1, 1...., 2002, 2,.35- 2...,.....

, 2001, 2,.20- 3. Dimmeler S., Zeiher A.M. Nitric oxide and apoptosis: Another paradigm for the double-edged role of nitric oxide.

Nitric Oxide, 1997, N1, p.275 4. Froelich C.J., Dixit V.M., Yang X. Lymphocyte granule-mediated apoptosis: Matters of viral mimicry and deadly proteases. Immunol. Today, 1998, v.19, p.30 5. Jimbow K., Prota G., Quevedo W.C. Biology of melanocytes. In: Freedberg I.M., Eisen A.Z., Wolff E., Austen K.F., Goldsmith L.A., Katz S.I., Fitzpatrick T.B., eds. Fitzpatricks Dermatology in General Medicine. 5th edn.

McGraw-Hill, 1998, p.192- 6. Le Poole I.C., van den Wijngaard R.M., Westerhof W., Das P.K. Presence of T cells and macrophages in inammatory vitiligo skin parallels melanocyte disappearance. Am. J. Pathol., 1996, v.148, p.1219 7. Nagata S. Apoptosis by death factor. Cell, 1997, v.88, p.355 8. Rivoltini L., Radrizzani M., Accornero P., Squarcina P. et al. Human melanoma-reactive CD4+ and CD8+ CTL clones resist Fas ligand-induced apoptosis and use Fas/Fas ligand-independent mechanisms for tumor killing. J.

Immunol., 1998, v.161, p.1220 9. Savill J. Recognition and phagocytosis of cells undergoing apoptosis. Brit. Med. Bull., 1997, v.53, p.491 10. Taylor S.C. Skin of color: Biology, structure, function, and implications for dermatologic disease. J. Am. Acad.

Dermatol., 2002, v.46, N2, p.41- DISTURBANCES OF SKIN PIGMENTATION AND APOPTOSIS R. Ismailov Republican Dermatovenereologic Dispensary, Baku, Azerbaijan The aim of analysis was to research the immune mechanisms of apoptosis in melanohenesus upset.

There were 226 patients under observation: 91 (40, 3%)-I group from them with vitiligo, II pigmented nevus-78 (34,5%), III group melazm-57 (25,2%) in the age from 16 to 55 (mean age-36,5).

157 were women, 69-men. Control group-40 person with undisturbed pigmentation. Analyses were made blood serum. Immunological tests of 2 levels were applied: phenotyping of leucocytes (CD3+, CD4+, CD8+, CD16+, CD25+, CD71+, CD95+, HLA-DR), used in it homogeneous antibodies, traced FITC, by the method of ow cytouorimetria. Level of interleukin production (IL)- IL-1b, IL-2, IL-6, IL-8 were determined by solid phase imunoenzymatic method with the help of test system for IFA with the further spectrophotometrication on the given wave length. Results are statistically worked up on Statistica program. Presence of T-cellular immunodeciency was determined. General for patients with depigmentation parallel increase of content CD25+, HLA-DR and IL-8. Apparently, damage of melanocytes connected with apoptosis disturbance.

# 1,.,.

,, - ),, ;

. ,,, -,, - (, ), 2-, 5 - ;

. -, (3,5,6,).

,., 20%,,,. -, - ( 4 ).

, 50% 70 -., :

- ;

, - ;

-, (. -., Candida,, - ) 40-60%., - ;

,,. ( 1,2 ).

, -,, - -,,, -.. -450-. -,. - (2).

: - ( ) - ( # 1,,..,,.

. - 12-16 (81 ),, - (1). ( ) - (3. -,2 ,, 7-14 )..

, 18 (25 ). - - -.

- 4, 8 12 9.

- :. - 400 Trichophyton rubrum, 11 Trichophyton 1, 3- - rubrum, Candida albicans, 10 , Candida albicans Trichophyton rubrum.

100mg, 3. -, ( -,,, ) ( )., -., Candida albicans, : -., 99 18 72.

. - -,. -, -.

..(5),,,, - -. -.

# 1, 1... ( ) , 3, 2004,.60 61.

2...,..,..,.. .. . 7. 1, 2005..1-5.

3...,..,..,, 1999, 3,.46-47.

4...,.. : .Consilium Medicum. , 2005,.4-6.

5...., 1999. 32.

6...,.. . , 1, 2005.. 91-94.

7. DeDoncker P., Decroix J., Pierard GE, Roeland D, Woestenborghs R, Jacqmin P, Odds F, Heremans A, Dockx P, Rpseeuw D. Antifungal pulse therapy for unychomycosis. A pharmacokinetic and pharmacodynamic investigation of monthly cycles of 1-week pulse therapy with intraconazole. Archiv Dermatology 1996;

132(1): 34- ORUNGAL IN ONYCHOMYCOSIS TREATMENT T. Kituashvili, O.Kvlividze S/R Institute of Dermatology and Venereology The purpose of the study is to observe systemic anti-fungous effectiveness of Itraconazol (orungal) in treatment onychomycosis of hand and foot by pulse-therapy.

Under observation were 99 patients with onychomycosis aged 18-72. Diagnosis was conrmed by microscopic and cultural study. Sergeev I. offered KIOTOS index to determine the method of treatment.

For this were dened the clinical form of the disease, the depth of lesion, the rate of hyperkeratosis, site of lesion and patients age.

According to KIOTOS index was determined the antifungal treatment. Patients with index 12- (74 cases), went under systemic antifungal treatment with orungal (itraconazol) by the regiment of pulse therapy (3 one-week pulse cycle with three-week dosage intervals in foot onychomycosis treatment, cycle in hand onychomycosis treatment). Local treatment was not observed. Patients with index 18 ( cases) above orungal pulse-therapy were treated by local keratolytic drugs. Patients were observed before the treatment and after 4, 8 and12 weeks of treatment initiation.

Before the treatment in 71 patients was detected Tricophyton rubrum in the pure culture, in 11 patients - Tricophyton rubrum and mold fungi, in 7 patients (hand onychomycosis) only Candida albicans and in 10 patients with hand anychomycosis candida albicans and Trichopyton rubrum.

The results show that after the rst course of the pulse-therapy treatment s healthy nails tarted to grow and after the treatment the symptoms of onychomycosis (dyscromia, fractures, onycholisis, hyperkeratos) completely disappeared in all cases. Onychomycosis treatment caused by dermatots, mold fungi and candida albicans were equally effective. The drug is tolerable, side effects were not observed.

So, orungal monotherapy of hand and foot onychomycosis of different severity and aetiology by pulse-therapy is very effective and easy-to-use treatment.

# 1,.,.,.

.

x.) (6,7).

( )., -.,, -, -,x, -,, - PBL (problem based learning), (4). ( ) -.

x, - 90-x (5,7). xo - : x (3)., x, 1997-1998. x -. : x x - ,, PBL- x x, x, (. x - ) x ( ) -, x.. x 1999- :, 2005. 180, x x x x., x x, x x x PBL .

. x, (4,5).,, x x -. x - -, - x. x x,,. -,.

x 60 x,., - (PBL) x x x, x x( - x x, x, x x,.

# 1, x x - x x ;

2) x x x.,, - x ;

3) x x x, - x, x.. x,, - x,, x -,,.x.

x. x x x -, - x, x. - x :,. -,,., -,, (, ). x, x x.

, x, x. - x -. 3, x - x : I) x x. - x x PBL, - ;

2) x x, - x ;

3) x, x, x, - ;

4) x,. x.,, PBL -, x.,.,,. -.,,, x - .

- x3 x x, x, x (,, ), - Academy for Educational Development (AED),.. x, x x x - x x -. x : x, x -. x x x., x x, x x, x : I), -, - x. - :,, x, x, -,.;

2),. 15% x, x x, 70% - - x,, 15% - - :,. ;

3), - x :, x, ;

4) : - -. - - x: I) -.

x,, # 1, x 180 xx ( -,,,, ), -, x x 2., 15% x x .,. x -, x,, -., x. -, . x.

,, x -, - ( ) -,. -, x, x x - - x. x. x x, xx x,, x x x,. x - x x x, x..

I..., -, 1998, 85.

2...,..,...

. -, 2003, 3,. 56-60.

3...,.... x, 2003, 2,. 3-4.

4... ( ) // x. 1996. - I0, -. 8-13.

5...,... -. 1998,. 62.

6...... 2000, I. . 28-31.

FAMILY MEDICINE AND DERMATOVENEREOLOGICAL PROBLEMS E.E. Danielyan, K. R. Babayan, I. E. Danielyan key words: family medicine, family doctor, dermatovenereology, dermatosis.

180 family doctors were prepared in Yerevan during 1999-2005y. by means of PBL and traditional methods. Most of the family doctors were employed. They can correctly manage the skin diseases and STIs staying in connections with dermatovenereologists. In cases when they can manage, they diagnose skin diseases and STIs, provide primary care, hospitalize patients with chronic dermatosis and manage follow up them, solve psychological and social problems of the patients and their families.

# 1,.,.,.,.,.

, ( ).)..,,,,, [6]. -, 2%, [5].

2-4,, 7,5,,... (1993),, 197,5 100 000...,, [1].

1995 90,2 100. -. - (,, ( ) 20-24,, ). ( 25 ) - (,. -,, ).

, - :

, -,..,, - -,, ;

[7].,.. ;

,,, (, );

, -, ( - ;

,, -.

# 1, - (210.) 38,95% (134.).

,, -, -, -. 2, - 3.

[4].,. 36, - :, - 12 (33,3%),,,,, - 2 (5,6%), 8 (22,2%), [3]. 14 (38,9%).

, - , - (82,8%), - (6,1%) 9 (2,6%), ,. (1,7%), 4 (1,2%). 19 (5,4%) - -. : 10 (2,9%), : 2000 2005 - (1,5%), 4 (1,2%).

, 1391 0 14 - 89, 15, - 1302., -,, - :. 47 (13,6%) ;

.

-, ;

,, 28,15% - -, -, ;

( ) -.

;

,,, ;

;

.,,. , : 1122,, (80,8%). - 344 (28,15%),. 61,05%.

# 1, 1. Akovbyan V.A, Kubanova A.A, et al. Epidemiology of urogenital chlamydiosis in the Russion Federation. Proc 3 rd Meet Eur Soc chlam Res 11-14 Sept. 1996, Vienna, p 398.

2..,..,. 2003.

, 97, 107.

3..,.../.., 2002, 1 2.25-30.

4..,... - - // ( ). 1995,. 5..,.. :, -. Med-Lib banner Exchanger.

6...,. 1997. 5, 65.

7. Davies H.D., Wang E.F, Periodic health examination. 1996 update: Screening for Chlamydia infections.

REVEALING AND CLINICAL COURSE OF GENITAL CHLAMYDIOSIS IN WOMEN N. Chkhikvishvili, M. Shvelidze, I. Rusadze, M. Pavliashvili, T. Kachakhidze S/R Institute of Dermatology and Venereology The goal of investigaition was the study of urogenital deseases in women with Chlamydial infection in Gonorrhea department of Research Jnstitute of Dermatologe and Venereology last 5 year patients were investigated. In complex of studies was included serological, bacterioscopic and cultural methods of investigation. 1122 (80,8%) patients were revealed. Chlamydial infection was diagnosed in 344 (28,15%) from them monoinfection in 210 (61,05%) case, mixed infection in 134 (38,95%) case. Clinical diagnosis was endocervicitis in 285 (82,8%). Endocervicitis and urethritis together in (6,1%) and thistoutethritis in 9 (2,6%). Vulvovaginitis in 6 (1,7%), conjunctivitis in 4 (1,2%) patient.

The 19 (5,4%) patients was diagnost lesion of upper urogenital tract: adnexitis in 10 (2,9), salpingitis in 5 (1,5%) pielonephritis in 4 (1,4%).

So, the results of the study shows that from investigated women with inammatory urogenital deseas in 28,15% was diagnosed Chlamydial, as mono and mixed infections. In the majority of cases clinical diagnosis was endocervicitis with next complication.

# 1,,.,.

,, - ( ) -,.

, - :

( ), -,, [1]. - (16PF), (, ( ) - 1 ),.. -, 30 -.

, [5]. - :,,,.. ;

- ( 1);

[3]..

, - -,,. ( : - B, M, Q1);

, -,, 30 18-26, -,,. ( -, C, G, I, O, Q3, Q4);

-,,,,. -,,, -, ( /187./ [4] - /8./ [1]. A, H, F, E, N, L, Q2).

, -,,, # 1,, -,.,, ;

- ( ). -, :, -.

-,,.,, :,, :, -,,, ;

-.

- -, -, / -,,, -,.

1..,.,.,,.. 1988, 200.

2.....1991, 200.

3...,.., -.

2000,6:31-36.

4. Cattell R.B. The scientic analisis of personality. Baltimore. 1965.

5. Kuiken C.L., Van Griensven G.J., de Vroome E.M., Countinho R.A. Risk factors and changes in behavior in male homosexuals who seroconverted for human immunodeciency virus antibodies. Am J Epidemiol 1990;

132:530-532.

PSYCHOLOGICAL CHARACTERISTICS OF COMMERCIAL SEX WORKERS Y. H. Shatvoryan, A. A. Grigoryan Yerevan State Medical University, chair of dermatology, STI and cosmetology key words: psychosocial surveys, commercial sex workers 30 women doing commercial sex workers have been tested by survey of Kettle and colour test of Lusher. Revealed data allow characterizing them as persons with intelligence abilities lower than mean level of population, isolated, lled with a lot of inner conicts and with high level of anxiety, forming nuclear social group. So education of safe sex, STI/HIV preventive methods must be performed according to psychological characteristics of this risky group.

# 1, Mycoplasma hominis Ureaplasma urealyticum.,.

, - -,,,.,, - ( ) -, -.

,, -,, N. gonorrhoeae, ( ), - T. vaginalis, C. albicans.

, - C. trachomatis Mobiluncus spp., Peptococcus spp., ( IgG Peptostreptococcus spp., Streptococcus milleri, Streptococcus IgA ;

ImmunoCombR, Israel) ., ( [1]., ;

- Gardnerella vaginalis. - 2).

- U. urealyticum M. hominis, Mycoplasma, hominis, Ureaplasma urealyticum.., MYCOPLASMA DUO (Sano Diagnostics Pasteur, France);

Mycoplasma hominis 1958. Hunter 24- Long, Taylor-Robinson 370 [10].

McConnack [2,3]. : 1) ( 4,5);

2) Mycoplasma hominis - - 10% ( - [4-7]. 10 %, - );

3) Ureaplasma urealyticum - (, -, 46% [8,9].,, Gardnerella vaginalis).

2004. - 375 - 14 (3,7%), 375 . 2 (0,5%), 15 (4,0%),, 16 42. 8 (2,1%), 183 (48,8%) # 1,. (.1). (I ) 2..

79 (43,2%), - -. EPI-INFO 6.0, SPSS 6.0. t ( - -.

, ) : II III - 1- -, Mycoplasma hominis (1, Gardnerella : n=42), Ureaplasma urealyticum (2- vaginalis. : n=26) (3, - : n=11).

, 53,2% 1- (n=42) 3 : 1- Mycoplasma hominis, Mycoplasma hominis (n=42), 2- - Ureaplasma urealyticum (n=26), (n=25). - 3- Mycoplasma ( =0,05).

hominis Ureaplasma urealy-ticum (n=11). 32,9% 2- (n=26) 104 (56,8%) - Ureaplasma urealyticum.,., 9 25 (36%) (n=25). # 1, ( =0,2)., 11,4% 3- (n=11) - Ureaplasma urealyticum, Ureaplasma Mycoplasma hominis., urealyticum Mycoplasma hominis. - Ureaplasma urealyticum, -, ( =0,05):. - -, 2.

, -.

Mycoplasma,, hominis: - Mycoplasma hominis,. Ureaplasma urealyticum.

1.... - 2001;

363.

2. Hunter C.A., Long K.R. A study of the microbiological ora of the vagin. Am J Obstet Gynecol 1958;

75:865 871.

3. Taylor-Robinson D., McConnack W.M. The genital mycoplasmas. N. Engl. J Med 1980;

302:1003-1010.

4. Hoist E., Wathne B., Hovelius B., Mardh P-A. Bacterial vaginosis: micro-biological and clinical ndings. Eur J Clin Microbiol 1987;

536-541.

5. Lefevre J.C., Averous S., Bauriaud R. et al. Lower genital tract infections in women: comparison of clinical and epidemiological ndings with microbio-logy. Sex Transm Dis 1988;

15:110-113.

6. Miettinen A. Mycoplasma hominis in patients with pelvic inammatory di-sease. Isr J Med Sci 1987;

3:713-716.

7. Paavonen J., Miettinen A. et al. Mycoplasma hominis in non-specic vaginitis. Sex Transm Dis Supple 1983;

10:271 275.

8. Blackwell A.L. et al. Anaerobic vaginosis (non-specic vaginitis): clinical, microbiological and therapeutic ndings. Lancet 1983;

ii:1379-1382.

9. Priestley CJ, Jones BM, Dhar J, Goodwin L. Whot is normal vaginal ora? Genitourin Med 1997;

73(1):23-28.

10...,..,... -. - 1999,2:43-45.

THE ROLE OF MYCOPLASMA HOMINIS AND UREAPLASMA UREALYTICUM IN THE DEVELOPMENT OF VAGINAL BACTERIOSIS Kh. Khachikyan, K. Babayan Medical - Scientic Center of Dermatology&STI In this article is illustrated the result of examination of patients (183 com-mercial sex workers) with bacterial vaginosis and control group consisted of 25 patients with normal compound of vaginal microora (rst degree cleannes), thuse was observated in 2004 in the SMD and STI Medical Center of Yerevan, Republic Armenia.

Thus the conclusion is bacterial vaginosis is associated with Mycoplasma hominis to a considerable extent more than with Ureaplasma urealyticum.

# 1, .,.,.,.,.,.,.,.,.

,, , -., -, . ,. [5}.

- , - [6].

,, [1]. -.

,,,,,. [2]. -.

, -,,, - [3]. - ,, [3] -,. - [4]. - :

., - ) - - ;

. - ) 420,;

, 14%, 5%,, 3-5%.. ), - ( ),, 6-8 20% 14-15%. - 60-62%;

5%,, - ),, 0,5% 2%, -. - 1,8-1,9. # 1, - 2 ;

0,5 1-2 2.

) - -,,., - 2-3., - 4-5. 7-14.

..

- 86%, 14%. - -. -, 27, -.

, 17 80 ;

25. - 24, -.

17, 11., 16, 6-7, 2-, 10, 5, 3-, 3-, 1- ,, 1-, 11. -.

1....., 2000.

2..,., 1999.

3....., 1992.

4...,.., 1986.

5....., 1986.

6. 278/4.

WORKING OUT THE TECHNOLOGY OF THE OINTMENT,,GERPESIN AND ITS CLINICAL INVESTIGATION B.Chlaidze, P.Iavich, T. Vartapetova, G.Tvaliashvili, M. Tevzadze, N.Rusadze, G.Tizhoev,M.Maridashvili,V. Kvirkvelia S/R Institute of Dermatology and Venereology Was worked out the the ointment,,Gerpesin for the treatment of different kinds of gerpes.The ointment is a mixture of plant extracts made in special way. The ointment has passed tests in Joint-StockCompani Institute of Dermatology and Venerology on patients. The results showed that the ointment is a good remedy for gerpes treatment and is recommended for the practical use.

# 1, (, ).,.,.,.,.

,.,.,.,..

# 1, c # 1, # 1,, # 1, # 1, # 1,,.,.

, -,, , -,,, - (,..),. - [3, 4, 6, 9, 10].

20-30%,, - (,, ,. ),, [1, 2, 6, 16, 17].

-,, -, [4, 13]..,, -, -,,,,, [13, 16, 17]. [12, 13,, - 17].,., -, [1, 2, 5, 16]. -. [10, 11, 15].

( ). -, 30 [13, 14, 15, 16, 17]., 10 12-18,..,, -,,,, - Trichophyton rubrum (75%),, - - Tr.mentagrophytes (9,8%), 15,, - Epidermophyton Floccosam (5,5%),., - (6,3%) (3%).

# 1, - ( - (Pityriasis Tinea ), - versicolor) Malasseria. furfur Pityrosparum orbuculare.

Microsporum canis (lanosum) 45,3%, -, Trichophyton faviforme 28,0%, - Trich. gypseum 15,7%, Micr. ferrugineum 4,8%, Trich. [9, 10].

violaceum 6,2%. , - -, (, ) (-,,,, ), -.

, - -, 21.., 40, - ( 1).

, ( ) 1, -.,, -. 891 250, ;

(43,3%), 847 (41,6%) 300 (14,1%). 5 72. 231 -, , - 3-., ( 4-6, 9- 1807 - ),.,.. 150., 25,,, 2%,,, (,, (,,.). 5,,, -, ),, (, ),, - (,,,,.., ). # 1,, -,. 50 -,. 10-20 - 94 / (3/4 125 ),. 20-40. 187 / (1,5 125 ), 40 250 /, -,,, 7 /, 500. 6-8 150,, 144 (96%), [7, 11] 142 (94,6%).,,. - 10,, - 2%.. - -. -,,. - .

: 1,2% -,,., - 3%, (3,7%) 0,1%. -, -.

., -, -..

- 10-15, . /. 4 3-,.

.., 5 -. / 1 3 -.

,, -,. (350 ) - 10- -. T,, -. 87,3%, . - 84,2%. 229 (89,3%), 224.

(87,5%)., ( )., 136 58, -. - 52, -, 26.,,.

# 1, 1...,..,..,.. ( ). //.. 2000, N 3, c. 71-72.

2... :,,. // , 1999, N 1- (5-6) c.22-24.

3.... //. 2001,.9, N 11, c. 471 473.

4...,.., ( ). //.., 2000, N 3, c.31-35.

5...,..,..,... //.., 2000, N 5,.27-29.

6...,.. ( ). //..., 1994, N 4,.10-12.

7...,..,.... //.. 1996, N 2,.61-62.

8... //..., 2000, N 1 (9),. 58-61.

9...,.. -. //..

.. 1998, N 2,. 54-56.

10... ( )... . 2001, N 4,.72-74.

11.... //... 2000, N 5,. 69-72.

12.... //. , 1999, N 10,.1-4.

13. Buchvald J., Buchvald D. (, Sandoz) 5-. // ( ).., 1998,.15.

14. Chang P., Logemann H.. // Int. J.., 1994, 33:8, 550.

15. Ewans E.G., Sugurgeirssen B. -. // Brit.

Med. J., 1999, N 4, v. 318, P. 1031-1035.

16. Hall M., Monka K., Krupp O., OSullivan D..//..

., 2002, N 4(18),.4-11.

17. Waston A.B., Marley I.E., Ellis D.H., Williams T., Long-term fallow up of pacients with toenail onychomycosis after treatment with terbinane. // Aust. J. Dermatol., 1998, 39, 29-30.

OUR STRATEGY OF TREATMENT OF SKIN, HAIR AND NAILS FUNGAL DISEASES E. Danielyan, K. Babayan Medical - Scientic Center of Dermatology and STI key words: mycosis, Terbisil, systemic treatment, local treatment Data of three years duration investigation of therapeutic effectiveness and compliance of systemic antifungal drug Terbisil (JC Gedeon Richter, Hungary) during fungal diseases of the skin, hair and nail are shown. Investigation has been performed in dermatovenereological establishments of the city of Yerevan by 40 specialists. Analysis of the data shows high effectiveness of Terbisil against onychomycosis, tinea pedis, microsporium infection and other fungal diseases of the skin and smooth skin and hair.

# 1,

.,..,., ;

,, -,,,, - 16-19, 17, 4% 20 ;

, ( );

, -. 44,8% ( ), 2002. ( ). -.

,. 2000-2002..

- 3,5. 2000.

., -, -,,,,...

. -, ( ), - 2000., - -, / - 20 ;

,., - ( );

, ( ) ( ).

,.,,, 320% 1986 ( ). 2001.,, -,,., -. 40% - # 1, -, (GFATM, Save the hildren, ). - ,. IX,.,, -,,,..,,.

,,,, -.., - ,, -,, ,,.. -,.,. -,.

, -,,.

(VCT). -.., 5 -, -.

,, ,. 20.1%, 2005 20.8%, 18,9%, - 4216, - 251, - 673, 7%. 56., - ( - 2005 ).

,.., -,,.,, -.,.

-,, -,. - -., -,, -.,, -,, -,.

. -, ( ), -,,.

, - -,, -.,,, -,.

# 1,,, -.. -.,,,..

-,, -.

, ,., - -, - 17,7%;

24,2%;

19,4%;

,. 13,8%...

,,., -. -,., -,. 18,8%, 30,7% 29%, -,, 5,7% ( ) -,. -..,, -. - -,., -,,, -. -,, -.

,,. ., -. (ESSTI)., J., Fertenberry.,. (1-3.) -,, (26%) (64%)..

,.,, -,.,, -,,,.

# 1, 1...,..,,... -. 2000. 5. 4-6.

2.,... -..2001. 6. 46-50.

3. Fertenberry J.D., Brizendine E.J., Katz B.P., Orr D.P.//Sex. Transm. Infect.-2002.-Vol.78, 5.-P.365-368.

4...,.... -... -.. 2005. 2. 67-70.

5. Jana S., Singh S. Beyond medical model of STD intervention-lessons from Sonagachi. Indian Journal of Public Health 1995;

39 (31:125-31).

6. Delvaux T., Grabbe F., Seng S, et al. The need for family planning and safe abortion services among women sex workers seeking STI care in Cambodia. Reproductive Health Matters 2003;

11 (21): 88-95.

7..,.,, :..... 2004. 1. 3-12.

8. Measure Evaluation. Sexual behavior, HIV and fertility trends: a comparative annalysis of six countries. USAID, 2003.

9. Cates W. the ABC to Z approach: condoms are one element in a comprehensive approach to STI/HIV prevention.

Network 2003;

22.

10.. /..

... 2004. 4. 16-17.

11. GRASP Steering Group. The gonococcal resistance to antimicrobials surveillance programme (GRASP) year report. London: Health Protection Agency, 2004.

12.. 2001.

13......... / -,,... -. 2003. 3. 16-17.

14..... :..... 2004. 3. 26-32.

# 1,.,.,.

,, -. -,, - :., ;

. :,, - ., -,, -, - , - ( FeS 0,08 0,16%, 0,,. 0,50%).,,,,,, - -, - 1.1.,. -, -.

, - ,,, -,.

, -,,., 1.,., -. -,. -15, 1 -,,, 2-6% - ( 10 1.

# 1, 1 )., -,. -. -, - -.

., - ,. (103-106), ( 10 103,, - 1 ). ( 1).

.

/ 10 - 10 10 - 10 - 10 10 - 10 - 10 10 - 10 10 10 - 10 - 10 10 - 10 - 10 10 - 10 10 - 10 - 10 10 - 10 - 10 10 - 10 - 10 10 - 10 - 10 10 - - - 0,1 - 1 0,1 -, -,..

,,, - : -,, -,,, c.

., ( -, , - ).,, - ( - ).

., # 1,, -,,. - (. )., -.,. -,..

1. kereseliZe m. klinikuri baqteriologia. Tbilisi 2001, gv.41-58.

2. bokuCava n. samkurnalo talaxebidan li pidebis miRebis meTodi. stu 8 wlisTavisadmi miZRvnili prof. masw. saiubileo samec. teq. konf. moxseneba Tezisebi, Tbilisi 2002, gv.69.

3. bokuCava n. mikroorganizmebis ekologiuri mniSvneloba talaxebis hidroqimiuri reJimis formirebaSi.

meoTxe resp. samec. meToduri konferencia qimiaSi, Tbilisi 2002, gv.86.

4...,..., 2004,.7,.30-31.

5... : -,,., 2005.

ANTIBACTERIAL PROPERTIES AND PHYSIOLOGICAL GROUPS OF MICROORGANISMS IN PELOIDS OF GEORGIA M.Mikaia, N.Spiranti, N.Bokuchava S/R Institute of Dermatology and Venereology, Tbilisi, Georgia For the rst time in Georgia in knoll and silt muds were found physiological groups of microorganisms, which take part in the process of formation of mud and give it bactericidal and adsorbing properties.

Its set, that different kinds of therapeutic muds are characterized by different biological avtivity.

They keep antibacterial activity at the quite enduring time, which shows that their activity is stable.

So you can use muds in non-resort atmosphere.

# 1,..,..

,, - ( ), [2].

,., - / 3-.

1999. 467,8 ( ), 2004 834,0. ( ).,, -- . -, , - -,, [6].

,. -,, / - : 1500 ( ) [4],.., - 7000-8000 [1]., ( ), -,,, : 55,6% 1995. 58,2% 2004. (.1) [3,7].

# 1,,, : - 64,2%, 22,4%, - 10,3%, 3,0%.. M :,,, - 232, - - ,,,,.

,. (64,2%), 25-. - 33,6%. - Moses (1992): 60%,., :, - [5]. 10,3%,,, -- 22,4%,, -., - 41,0% 36,1%.

. -, SSPS. - 42,6%. : - 71,9%, 57% 14 52. -, 47,7%, 75%, 75% 25-29 - 30,2%. -, 75,5%, 29,7. - 71,4%,. 4 24 (10,3%), ( ) 91 (39,2%), 58 (25,4%),.

35 (15,1%), 22 (9,2%).. 25 29 52 41,2%, : 41,1% (22,4%), 54 (23,2%), 39,4%. 1-2 - 60,8% 85 (36,6%).

19 (8,2%), 22., (9,5%)., : 85 (36,6%), /, 84 (36,2%), 49 (21,1%), 5 (2,2%), 9 (3,9%).,,, -, 58,6%. -. 137 (59,1%) -., -, 17., (7,3%). 3 -,,,,..

232 5 (2,2%),,. : 26 (11,3%), o 86 (37,1%), 24 (10,4%), 8 (3,5%),, 66 (28,7%), / 2 (0,9%), 32 (13,9), 7 (3,0%)., 8..

# 1, 1. HIV Surveillance in the Republic of Armenia 2002;

2. Adler MW. Sexually transmitted diseases control in developing countries. Genitorium Med 1996;

3. Babayan K R Armenia: reducing sexually transmitted infection among CSWs. Entre Nours 2002;

N53:14.

4. Daj S., Ward H. Sex workers and the control of sexually transmitted diseases. J Genit Med 1997;

73:161- 5. Moses S. Manji F, Bradley JS, et al. Impact of uzer fees on attendanse at a referal centre for sexually transmitted diseses in Kenya. Lancet 1992;

340:463-466).

6...,..,..,,,.

1998;

1:4-6.

7. 2004.

RISK FOR GETTING SEXUALLY TRANSMITTED INFECTIONS AND WOMEN COMMERCIAL SEX WORKER E. Shatvoryan, M.Mirakyan Yerevan State Medical University, chair of dermatology, STI and cosmetology The survey of 232 male patients, who have sought medical consultancy in dermatovenereological clinics with genitourinary complains, and observation of their medical records have been performed in order to reveal the role of women doing commercial sex work in transmission of STIs. The data have shown that awareness of those patients is very low: HIV/STI 58.6%, condoms 59.1%, use of condom 7.3%. Only 2.2% of the observed patients were healthy and 11.3% of them had gonorrhoea, 37.1% trichomoniasis, 10.4% genitourinary chlamidiasis, 3.5% mycoplasmosis, 28.7% nongonococcal urethriris, 13.9% syphilis, 0.9% genital warts, 3.0% genital herpes. The sources of infection in most cases in all age groups were women doing commercial sex work 64.2% and casual sex partners 22.4%. 36.1% of married and 41.0% of divorced patients mentioned women doing commercial sex work as a source of infection.

In conclusion, we can declare that the assumption about women doing commercial sex work as a highest risk group in transmission of STI is real and proved. So it is a must to increase the awareness of women doing commercial sex work and the public about HIV/STI and their preventive measures.

# 1,.,.,..

,, C - ( -) ( ) - ( ). (1,3)., - t-.

,,,, -., -. -. - Ag-NOR.

-..,, 9.73.18 /,,, -, (1).

, (4). -. - (n=30) 14.6 4.81 /. I 30, 9 52 ( 25.3 12.37 4.4 /. 11.42). 30 18, - 12. -. -. - 17.14.9 /. III. 30 - 13.574 /., 10. I 7 3 ( ). 5 5 - 30 (extensive), - ( =0.0017)., -,. III, 6 4 - ( =0.0008).

( ). - 10 (7 3 ). ( =0.057).

- # 1, - I ( =0.17). et al., (2004), - Teraki et al., (1996), I II ( =0.047). III ( -. ) I II ( 0.6, 0.1).. 5.3 2.39 /.. - - (2). - 30 14.0611.4 /, -, 3, -,. I -. - 10.16 10.06 /.,, -, II 21.78 10.8 /. -.

, I III -, c - -. III -.

10.24 10.12 /,. - - - -. 30 - ( = 0.0003). - Ag-NOR. -, II ( =0.0001)., I III 2,, ( -. -0.15). -, Ag- ( ). -., 3- -, II I, II III (.

0.02). I III ( = 0.99)., - 2-3 Ag-. Arca.

# 1, 1. Arka E., Musabak U., Akar A., Erbil AH., Tastan HB. Interferon-gamma in alopecia areata // Eur J Dermatol.

2004, 14, 33-36.

2. Honlinger M., Fuchs D., Hausen A., Reibnegger G., Schonitzr D. et al. Serum neopterin testing for additional safety in blood banking // Dtsch. Med. Wschz. 1989, 114, 172-176.

3. Teraki Y., Imanishi K., Shiohara T. Cytokines in alopecia areata: contrasting cytokine proles in localized form and extensive form (alopecia universalis) //Acta Dermato-Venereologica.1996, 76, 421-423.

4. Tobin D. Morogical analysis of hair follicles in alopecia areata // Microscopy Res. and Technique, 1997, 38, 443 451.

ALOPECIA AREATA: CLINICAL, IMMUNOLOGICAL AND MORPHOLOGICAL DIFFERENCES Lortkipanidze N., Tevzadze M., Nogaideli N.

S/R Institute of Dermatology and Venereology, Tbilisi, Georgia The aim of the study was to compare the serum levels of interferon-gamma (INF- ) and neopterin (NPT) in 30 patients with AA and the control group. We also investigated the difference between localized form of AA (I group), extensive form of AA (II group) and patients with family history of AA (III group).. The serum levels of INF- and NPT were measured using enzyme immunoassay techniques. The mean serum INF- level in control was 9.7 3.18 pg/mL. The mean serum INF level in AA patients (n = 30) was 14.64.81 pg/mL, whereas I group (n = 10) calculates 12.374. pg/mL;

II group (n = 10) - 17.14.87pg/mL and III group (n = 10) - 13.57 4.02 pg/mL. Serum levels of INF- in patients with AA were signicantly higher than those in controls (p=0.0017).

Signicant difference was observed in serum levels of INF- between patients with extensive form and control group (p=0.0008). Signicant difference was observed in serum levels of INF between patients II and I groups (p=0.047).The mean serum level NPT in control was 5.32. nmol/L;

in AA patients was 14.0611.4 nmol/L;

in I group it was equal to 10.1610.06 nmol/ L;

II group - 21.7810.8 nmol/L and III group - 10.24 10.12 nmol/L.Serum levels of NTP in patients with AA were signicantly higher than those in controls (p=0.0003). Signicant difference was observed in serum levels of NPT between patients with extensive form and control group (p=0.0001). Signicant difference was observed in serum levels of INF- between patients II and I groups (p=0.02) and II and III groups (p=0.02). Morphological analysis shows perifollicular and intrabulbar lymphohistiocitic inltrate, activation of epithelial and endothelial cells of hair follicles, by patients with extensive form. That was conrmed by matter and by nature of distribution of AgNOR-proteins in their nucleoli.

# 1, .,.,.,.,.,.,.,.,.,.

, -, ,, -., -.

. -,,.,,, -,.,. -,,, -.. -,.,,.., - -..,,,,., -.

,, (Nespilus germanica l.) ,, 1,5-6,0., -, -.

,,.. - -,, ,, -,, -.

,..

, 3 10, 2-4.. -,, ,, -,. .,,,,.

[1]., -,, # 1,,, -, 25%- [2]. -, ,. -.,, - [3],,. 76-83%. -, -, t=36-37.

, 1:10 - S.aureus 209- P;

S.aureus ;

S.aureus ;

S.aureus Wood-.

46;

E.coli 675;

E.coli 055;

Paracoli;

Salmonella Buslaw;

Shigella Sonnei;

Bac. antracoides-96;

Bac. antracoides-1;

Bac. :

Subtilesi L-2;

Candida Albicans. - ) ;

) - ;

).,....,. :

., 6,1-6,3 10%-, ;

4,, - . - ;

2,49 .

20.

10- 25%. 14. 30-35., 2,0 3,0..,, -, - 0,8-1,3 .,, ( )., - 2,0-3,0 ,..,,. -. -.

. 20%- -. -..... - 42. 42C. ;

3%-. - 3- ;

2- ;

. - 2- ;

25. 26 ( ) 16., 2 :) -. pH=6,5, - 0,5 12 2.

pH ;

). 2-3, 5-6 2-. ( ), 6 -.., -. 24. ,, - ,, .

,., 2-3, 5 - 6.. 2 # 1,., - .

.,. -, , -, ..

1...,..,..,, 1995.

2..,., 1999.

3. Adams A.U. Pharmacology of loguorice. Pharm. J. 1983, vol. 271, p.37.

WORKING OUT TECHNOLOGY AND CLINICAL INVESTIGATION OF THE OINTMENT,,MUSHMULINI G.Galdava, P.Iavich,T. Kituashvili, N.Gergaia,T. Vartapetova, K. Apridonidze, G.Tvaliashvili, I.Rusadze, M. Tevzadze, N. Rusadze Was worked out the ointment,,Mushmulinifor candida and microbic diseases treatment.

The ointment is a thick extract from,,Mespilus germanicaleaves, that is introduced into the base, containing MGD. During preliminary investigations the ointment showed activity against the series of shtams of microbes and candidas.The ointment has passed tests in Joint StockCompani Institute of Dermatology and Venerology. Were examined 42 patients.As the result of the obtained data the ointment,,Mush muliniis characterized by strongly pronounced antimicrobic and anticandida effect.The ointment is recommended for the practical use.

# 1, -.,. * ;

* ;

, -,,,, -., (1,2,3)., - (Chlamydia trachomatis, Ureaplasma - urealiticum, Tri homonas vaginalis, Neisseria gonnorrhoeae),,, - -,,,,.(2,4),. 3-,,, -, (5), -. -8 - -, (6,7). - IBL-HAMBURG, - 5 pg\ml.


. - -.

-8 ( -8), : -,, - -. - Chlamydia trachomatis 41 : 178 - (23%), Ureaplasma urealiticum 33(18,6%), Tri homonas - vaginalis 39(21,9%), Neisseria gonorrhoeae, 7(4%), 17 51 25. 49(27,5%) 9(5%) 85(47,8%) -8 -,, 93(52,2%). -, # 1,,, -., Chlamydia trachomatis, Ureaplasma urealiticum -8 25 - Tri homonas vaginalis.

. 0 128 \, 110 215 \. -. -8 750 2200 \ - 43(50,6%).

-8 -, 0 235 \,,. 52(56%) -. -8, 28(68,3%) (41 ). -8,, 17(20%) - 80 \, 12(29,3%) 80 165 \,, - (2,4%) - 2300 \ 3500 \, 235 \. -. -. -8,, 33(80,5%) 41,.

-,, -8 -8. 8(19,5%),.. -8 -., - -.

-8.

- :

8 1... -8. - -8,, 85, -, 250 3500 \, -. - -.

- 2. -8 250 2200 \, - -, 2300 \. -8 250 \ 700 \ 25(29,4%) -.

# 1, 1. burkaZe g. imunomorfologia - norma da paTologia, Tbilisi 2001 w. - 316 gv.

2... -. ,, 2002.

- 349 c.

3...,.... , 2003. - 442.

4..,.,..., ,. - 581.

5. Bansal A.S., Thomson A., Steadman C. et al. Serum levels of interleukin 8 and 10, interferon gamma, granulocytemacrophage colony stimulating factor and soluble CD23 in patients with primary sclerozing cholangitis.

Autoimmunity. 1997. - V.26. - p. 223-229.

6. Depuytdt C.E., Bosmans E., Zalata A., Schoonjans F., Comhaire F.H. The realation between reactive oxygen species and cytokines in andrological patients with or without male accessory gland infection. J. Andrology. 1996.- 6.- p. 699- 7. Koumantakis E., Matalliotakis I., Kuriaou D., Fragouli Y., Relakis K. Increased levels of interleukin-8 in human seminal plasma. Andrologia. 1998. V. -30. p. 339- THE CONTENT OF INTERLEUKIN-8 IN THE BLOOD AND EJACULATE IN CASES OF CHRONIC INFECTIOUS-INFLAMMATORY DISEASES OF UROGENITAL SYSTEM IN INFERTILE MEN G.Galdava, Sh.Chiokadze* S/R Institute of Dermatology and Venereology;

Health House LTD*;

Key words: IL-8, immunity, infertility.

In connection with great importance of interleukins in maintaining of homeostasis, extensive investigations for the study of synthesis process, production and efciency of interleukins in various pathologic processes, including inammatory diseases of male genital organs and infertility, have been carried out.

The study of interleukin-8(IL) content in the blood in cases of inammatory diseases of urogenital processes has revealed that in the majority of patients, the attempt to dene IL-8 in the blood serum failed, as for those in which this cytokin was defected in 33 (80,5%) infertile men with inammatory processes of urogenital system its concentration varied within the boundaries of IL concentration among practically healthy men. Only in 8(19,5%) patients content of IL-8 in the blood was higher standard indices. An attempt to reveal relation between various pathologies of genital organs and IL-8 content in the blood was also unsuccessful.

Thus for diagnostic point of view it is not advantageous to use these criteria in the blood in complex with other indices of local immunity.

Concentration of IL-8 in ejaculate varied in the range from 250 to 3500 pkg/ml i.e. was marked with high variability and was higher that the indices of healthy men. In cases of excretory toxic forms of infertility it was in the range from 250 to 2200 pkg/ml and from 2300pkg/ml and above in the presence of excretory and obtrusive forms. IL-8 should be studied in ejaculate together with the other parameters of local immunity as it gives more exhaustive information on inammatory processes of urogenital system in infertile men.

# 1,.,.

,, ( ), ( ), -,, 3 Borrelia burgdorferi sensu lato - 32 ( 7-10 ) 34-92%.

-,,, -,,, -.,. Borrelia burgdorferi. - 15.

: Borrelia burgdorferi sensu stricto, 50-80% B. Garinii, B. Afzelii, B. Japanica, B. Andersonii. :,,,,., -,. :. 6, Ixodes scapularis (, - ), Ixodes pacicus ( ), Ixodes ricinus ( ),, ( Ixodes persulcatus (,,, -,, ), ( )., ), ( ),.

.

(, -, - ( ).

.

. ( ), - ( ),,, -.

,,,. - - (1995),, -.

.

I ( ). 3-32., ELISA ( II ( ) ) 2-3. ( ).

III ( ).. # 1, ( -.

). : 2005. 100 2 ( );

:

, :,.. -,, 3-10, -.

., :,.,., -. -, -. :. -,,,. -.. 53 RPR T..

1............ 2001. 3..3- 2. Hergogova J. Lyme borreliosis. // Intern. J. Dermatol. 2001. V.40. P. 547-550.

3. Steer A. C. Lyme disease. // N. Engl. J. Med. 1989. V. 321. P. 586-596.

4...,....... 1997. 5.12-15.

5...,..,..... 1995 3.12- 6. Preac-Mursic V. Wilske B. Reinhardt S. // Eur. J. Mikrobiol. Infect. Dis. 1991. V. 10. P. 1076- 7. Wilske B. Preac-Mursic V. In: Weber K. Burgdorfer W (ed) Aspects of Lyme borreliosis. Springer. Berlin.

Heidelberg. New York, 1993.

8. Robertson J., Guy E., Andrews N. et al.// J. Clin. Microbiol. 2000. V.38. P 2097-2102.

9. Evans J. Lyme disease // Curr. Opin. Rhevmatol. 2000. V. 12.P. 311-317.

10...,..,..... 2000. 3..9- 11....... - ( ), 12... : -, 1998. 13........ - ( ), 2000. 160.

ON EPIDEMIOLOGY OF LYME DISEASE Buchukuri I., T. Kituashvili S/R Institute of Dermatology and Venereology, Tbilisi, Georgia Laim-Borrelia is a feral herd disease and poses hazard to peoples health due to its (chronic and polysystem) clinical course. The purpose of our article is to draw physicians attention to the rst stage of the disease chronic migrating erythema, as the only way of early detection of the disease. Early recognition is very vital to avoid LBs late manifestations like morphea, anetodermy, Pasini-Pierini atrophodermy and neuroborrelia.

In spring and summer of 2005 there were 5 cases of chronic migrating erythema at the Institute of Skin and Venereal Diseases of Georgia. All the patients marked stings and all of them had been in the east Georgia. As endemic areas of (Ixodidae) ticks havent been in Georgia yet, LB epidemiology needs advanced study. The article deals with the detection and treatment of this disease.

# 1, c.

,, -, 33,5%.

. - T.violoceum, T.mentagrophytes var. gypseum.

(2,3),, -,.,, - (5,4). 1970-79 -.

, XX -,,.

,,. - -., 70 XX. (1,6)..,, -,,, 80-85%,. 15-20%. (1960 80 ) - (T.violoceum),. - - - T.mentagrophytes var.gypseum. (5)., 66,5% - - M.canis. (.1) (1960-80 ) 84% - (T.volaceum) 4% - (T.mentagrophytes var. gypseum) 12% - (M.canis) # 1, 1980-90. -, 40%. -. -, (T.mentagrophytes var. gypseum)., T.mentagrophytes var. gypseum., -,,,,. -.

- c,,.

. 27,,.. -.

- 70%. -,,,,. 95%. -.( 2) ( ),. 90-95%, -. -.,,. 15-20% -.

. - 3 7 ( 3), -,,,. -,...

600 (1970-80 ), - ferrugenium, a M.canis.. 37 246, ,, 12 82, 24 318. 10 (6,3 -. 1 ). 6 - - 1 T.gypseum. 4 -, # 1, ( ),,, M.Canis, M.ferrugineum XX,.. - 3 7 ( 3).

.

03 37 7 ,. - (90-95%).. -., 10%. - ( M. anis ).

. -. ., -.

( 8-10 ).,,,,, - -,, T.mentagrophytes var. gypseum.

# 1, 1...,,. . (.., 1992., 3,.43-46) 2.... . (..

1991., 4,.46-49) 3... - . (,, 1966.,.210-220) 4. Ferragni Let.al. Mycosen(1993., 36..3-4,.135-137) 5.. - . (..

-., 1999.,.5-6) 6...,..,...,, . (2000. 2,.4) EPIDEMIOLOGY OF DERMATOPHYTOSIS WITH PREDOMINANT DAMAGE OF HAIRY PART OF HEAD IN GEORGIA G. Tvaliashvili S/R Institute of Dermatology and Venereology, Tbilisi, Georgia Dermatophytosis of the hairy part of head is one of the most common mycoses in the whole world. Their geographic distribution is not the same everywhere. In some countries microsporia takes the leading place among them. At the same time, in some republics of the former Soviet Union trichophytosis makes the majority of fungal diseases with the damage of hairy part of head. Antroponosic trichophytosis prevails in some of them, zooatroponosic trichophytosis does in the others.

In Georgia the struggle with dermatophytosis is constantly carried out. In 70s of XX century favus was practically liquidated. Trichophytosis used to take the rst place by the frequency of occurrence, antroponosic trichophytosis prevailed among dermatophytoses (pathogene T.

violaceum), whereas microsporia, brought about by M. ferrugineum was taking the second place.

Trichophytosis and microsporia brought about by zoophilic fungi was seldom monitored. For the last 20 years the fungal ora of these dermatophytoses sharply changed. The signicance of zooantroponosic trychophytosis increased (pathogene T. mentagrophytes var. gypseum).

Antroponosic trichophytosis is seldom monitored, antroponosic microsporia is almost liquidated.

In recent years microsporia is brought about by the fungus M. canis.

Sharp decrease of rate of sickness by dermatophytosis with predominant damage of hairy part of the head is caused by regular anti-epidemic measures carried out in the country.

# 1,.,.,.

, ( ).

1920-1921, - - (.

, 1919 ), :... (1927) -.. - (1929).

(1871-1936), -, -.... -.. 1922. 1930..

.... - 1924 -,..,.. - (... ),...

.... - ( 1924-1930.)..... (1930-1938 ),.. (1938-1946 ),..

-, (1946-1947 ).. (1947-1955 ).

8 - 1955..... - - -, -. 1972...,. 18.. (.. - 1991 ) :

.., (1991-1992 ),.. (1993-1997 ), 1997 -....

- 1925.

# 1, -, 1930.... ... - (1933-1937 1942-1962 ),. (1929),.. (1962-1980 )... (1980- 1930 1999 ), 2002 -.. - - ,,,..., 1928.. 1 -...... ., - 3 ( - -..., 1933);

- (1933),, - -.... - -,,..,..,.., -..,.,..,..,.

... 1938 -1964. 1930 - (1890-1964),, -..,...... - 1927,, :. -. 1930 2. . ..... -, - (1926). ..... - (1898 1962) 1933 1938....... - 1922 - -... 1923 1925, -,,.

,,,.,.. (..,.., ... ).

. 1925. .

1925.. -.

,,... - - -...

., -.

(1927-1931 ) -.. - (1946).. (1956).

(1936-1937 ).... 1937. 1942 1964 1968.

,....

1942 - (1880-1939) - - 1939,..,..

...... -,,,,. -.

# 1, 1950... (1927), -,., -...,...

....

- 1954.... - : (1929)... - ... 1935.. 1940 1964.

. 1954 1955 (1907-1987 )... 1929. - -.

, - 1955..,,, -,. 1935 -..

.,, 1936 . 1936.. 26 (1964-1990 ) 1991- -.

( ) . 1940 1969. -, - -.

. 1946 1964.....

-.

..... 76 -, -.

,, -, - -, (, ).

-.

.. 1965.. (1941 ),.. (1946),.. (1954 ), :.. (1964 ) -32 .

.. (1965 )... - - ,, -.

,......

, -,,, -....

......

1964-1990 - 1978,, -.

(1926-1999 ) , -,... .

1947. - -,.. -, - -. 9,. 2.

# 1, - ,. 9 -.,, 1994. - -.,, - ;

, -.

-....

,.. -, -, -.,,.

1991,. 1959 - -,..

- - - -... (..., (1952-1960 ). 1960 1964...,...,..,. 1964-1966..,..,..) 210 - -. 6 -. 1966, 2 4,.. 1 2,. - 1 2, - 1 6.,.. -...,. 1969.

.. -, -, - ,.,. 1970 - (.,, 1971 ),.... 200 1990.. -.

-... 1991 -, -, , -, 1992.. -,, - I -,.

.,,,.. -... - -.

. -.., -..

.. -,, -, -.., -,... -.

# 1,..

,,, -,,,,, -,, -.

. -,,,,,. II-.

,.,,, ( ),,, , -.

,., -,,,,,. -,,, -.

( ).

,,, -. -,.. - -..,, -,.

( ), -.. 1951...

- 1969..... 2,, - 743 -, - -.,,. - -.. 1934...

,.. 1955, ,, ,., 1953. 60300 -. 32 # 1,. -., (, ) - - -, (1956, 1963, 1968 ). ( ).

65, -,. - ( ) 1965. ( ). - - -,. 35. -, 42.

,5,2,2,1,1 - - 1, 188, -, 12.

5., -,,, -.

, -..,.

- 3,, 1971-73 - ( ),, -,,,, -,, -.

.. - 296 36, 18 15, 5 - -, -,2,2,2.

, 26 ( 12 -,,, 11 - - (, 3 ( - ).

),1, 18 ). (23 56), (15) : - (7).

,,, :,.,,., -.

. -. ,, -,, Nocardia asteroids,.,, 5 ( -,, -, ) - -.,. - -, # 1,. -,, :

, - 1., -,., 30 - ;

12,3 2.,3-,2-, 94 - (,, 45 - ;

5 ( - 3. ) ). 36 (20 -, 10 - - 6 - ).

1..... 1969. 461.

2..... 1973. 190.

3...,.... 1978. 328.

4..... 1982. 112.

5..... 1982. 115.

6...,.... 1983.

191.

7..... 1984. 224.

8...,.. (,..

.. ), 2002, 325.

9...,.... 2003. 439.

10...,..,..,..... 2003,6,36-37.

11. Dermatology in General Medicine. Th.B.Fitrpatrick;

A.R.Eisen;

K.Wolff. vol.II.1993.

12. Cutaneous presentations of cryptoccosis. M.Ballestero-Dier, J.Garcia-Rio gourhat of the European Academy of Dermatology and Venereology. Vol.16.suppl.1.2002.p.35.

13. Lichenoid id reaction in mycetoma: a case presentation. C.Ferreli, L.Atrori, gournal of the European Academy of Dermatology and Venereology. Vol.18. Suppl.2. 2004. p.165.

14. Sporotrichosis following mesotherapy. R.Gamo. A.Aquilar. gournal of the European Academy of Dermatology and Venereology. Vol.18. Suppl.2. 2004. p.166.

THE PROBLEMS OF DEEP MYCOSES IN GEORGIA K.Shvelidze S/R Institute of Dermatology and Venereology, Tbilisi, Georgia Deep mycoses is a group of chronic diseases caused by pathogenic fungi, which may affect skin, subcutaneous tissue and internal organs. Cases of coccidioidomycosis, sporotrichosis, chkromoblastomycosis, visceral and granulomatosis candidosis, pulmonary aspergillosis, actinomycosis, nocardiosis, mycetoma (Madura foot) and geotrichosis have been registered in Georgia. After many years of investigation we have come to the conclusion, that deep systematic mycoses are more frequent than it is revealed. The reason is that the patients are oen treated by surgeons, stomatologists, pulmonologists, therapists, gynecologists without the right diagnosis.

# 1,..,..

,., x ( ) x ( ) - 3-, - - 5-6-.

. x x x x -. 20 - - -I. x 25 x -. x 3 (,, 22. x, -,.). x.. ,, 16 x,, 9 ( 6, - x. 3). x ( 1- - ),,.

xo, - x x, x - ( x. - x. - x);

, x - x x,,..

:

..

, ,,...

,. -.. 61, # 1, 24. - -, :,,,,,..

, - : -.

;

- - ;

- 18+3,08.

;

. -.

.. -,,.

. -,. -.

..,..

,., -.,.. - 1921.,,,.

.,,, -,,.

-. 1971. N2.,. - -,, 6-.,.

1978. 40 ( .. ) 2-.. - , -..

-,, # 1, - (,,,, ;

..,..,.., ;

..,....).

.. ;

..

..

,, -, 66% - ( ) -.., -,. : 5 101 15.

( ), 1999. - 22, 9,7%,.

. 2000. 2004. 5 - :

.,.

, -,.. -, 31,3%, - ( )..

,. -, 19,. (0.63 10. 000.).. - 3,5 0,18..

, :.

I 22,4%, II 42,5% III 33,1%. 17% - -.

# 1,.

..,, - - ,,,, -,, - - -.

. -.

- -, ( ) -, ( ).. -.

: I 28, -, 16, - 12, 20 45, -. 2- ;

II-, 19, 16,, -3,. -.

, - 2, 4, 8 9, MMPI, mini- mult ( MMPI).,.,, -,,. -.

.,.,.,.,.,.,.,.

,., - ( ),,, -.

,,, - # 1,, - 41. - (19,8%). -. 22 (53,7%), -,, - 3 (7,3%), -. - 5 (12,2%), - 7 (17%),,,. 3 (7,3%), - 1(2,4%)., - 5. - :, - 30 (73%);

- - 7 (17.2%) - 1999 2003. - (9,8%).

,, (94,3%) 2722 (98%) , - 57 (2%).. : : 5 - - 17 (29,8%);

- 4434. - 5 (8,8%);

- 649 (14,7%);

536 (12%) 13 (22,8%);

-, 263 - 13 (22,8%);

- (5,9%), - 2 (3,5%);

2986 (67,4). : - 4(7 %);

- 207 (7%) 1(1,8 %);

- 192 (92,8%) 1 (1,8%);

15 (7,2%) 1 (1,8%).

166 (80%),, - 41 (19,8%) 907 (30,8%) 1506 (52%). 826 (91%) 826 (91%), 81 (8,9%) 183 (6,2%), 125 (4,2%) (70,4%) 79 (68%).

88(70,4%) (57 - 2%) 37 (29,6%) - 116 (3,93%) 26 (45,6%), 79 (68%) 22 (38,6%) - 37 (31%) 5 (8,8%).

183 (6,2%) : 5 20 (0,71%), 17 (0,6%) 57 -,,,,. -.

# 1,.

,, ( ) -, -,,,.. /.. / -.

. - : 34 14 50, 10 1,,, 18 16. 19 10. (55,9%), 5, 8 (23,5%) , 3 (8,8%)-,. 4 (11,8%) -. - 2. - -,- -., -.

, -.

. - - (/).

..

,,. - 2-. -, - 97, - 53,, 20.., - -. 85%., -,, - IgG IgA, IgM -.. -, # 1, - G, A, M - -, - - 20-40%. -, -, -..

-,.,. 89, 5% -. -., -.

..

,.,.

-,, -,,, -, 11.

. -, 3- -.

2001 2004. - 22- - 450. -,, -,,,., -. (3- : 275 - ).

. (170) - 125-, -.

,, - :

,,,,,,...

# 1, ..

,, ),,, (10- - ).

,. 68, 20 70, 39 29. - : -.

32, 20 13., - (,. ) ( -.

.,.,.

-,,.

. - 150 per os -, 150 per os. 2-.

. - 7, 14 30.

17 16 40, -. 4. - 9, -. 7. 9 -.

, 8-.. 10 (Jamanouchi) (100 ) ( ) ( )..

# 1,, :

1.

( Times New Roman, 12, 1.5, 3 )., Microsoft Word 1998-2003.

2. 4- 10,, ( 5-8 )..

3. : 1) ;

2) ( );

3),,.

4. 5.

5.

0,5.,, ( Key words ).

6.,, ( ).

7.

,.,,,,,,, (- ).

8.

.

9..

,, Microsoft Word, A4, 1,5. Times New Roman 12,.

: ;

;

;

;

;

;

;

.



 
 >>  ()





 
<<     |    
2013 www.libed.ru - -

, .
, , , , 1-2 .